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Summary (38/40) 
The efficacy of praziquantel against Schistosoma mansoni was significantly lower in 
Ugandan schools that had received more prior rounds of mass drug administration, as 
determined by fitting a statistical model to parasite egg counts before and after treatment. 
 
Abstract  
Background 
Mass drug administration (MDA) with praziquantel is the cornerstone of schistosomiasis 
control in sub-Saharan Africa. The effectiveness of this strategy is dependent on the 
continued high efficacy of praziquantel, however drug efficacy is rarely monitored using 
appropriate statistical approaches that can detect early signs of wane. 
 
Methods 
We conducted a repeated cross-sectional study, examining children infected with 
Schistosoma mansoni from 6 schools in Uganda that had previously received between 1 and 
9 rounds of MDA with praziquantel. We collected up to 12 S. mansoni egg counts from 414 
children aged 6-12 before and 25-27 days after treatment with praziquantel. We estimated 
individual patient egg reduction rates (ERRs) using a statistical model to explore the 
influence of covariates, including the number of prior MDA rounds. 
  
Results 
The average ERR among children within schools that had received 8 or 9 previous rounds 
of MDA (95% Bayesian credible interval (BCI) 88.23%, 93.64%) was statistically 
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significantly lower than the average in schools that had received 5 (95% BCI 96.13%, 
99.08%) or 1 (95% BCI 95.51%, 98.96%) round of MDA.  We estimate that 5.11%, 4.55% 
and 16.42% of children from schools that had received 1, 5, and 8/9 rounds of MDA 
respectively had ERRs below the 90% threshold of optimal praziquantel efficacy set by the 
World Health Organization.  
 
Conclusions 
The reduced efficacy of praziquantel in schools with a higher exposure to MDA may pose a 
threat to the effectiveness of schistosomiasis control programs. We call for the efficacy of 
anthelmintic drugs used in MDA to be closely monitored.  
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Introduction 
 
Schistosoma mansoni is a parasitic trematode and an aetiological agent of the neglected 
tropical disease schistosomiasis, which is estimated to infect over 230 million people 
worldwide [1]. The parasite has a complex lifecycle involving a snail intermediate host, 
with humans becoming infected through skin contact with infectious water sources. 
Chronic morbidity of intestinal schistosomiasis is caused by eggs from adult S. mansoni that 
become trapped in tissues. This leads to granuloma formation that can cause fibrosis and 
portal hypertension [2]. Conservative estimates of morbidity indicate that S. mansoni 
infection accounts for 4.4 million cases of blood in stool and 8.5 million cases of 
hepatomegaly in sub-Saharan Africa [3]. 
 
Interventions to control schistosomiasis have varied over time. Early national control 
programs, such as the Sudanese Blue Nile Health Project (started in 1979) and the Egyptian 
national program (started in 1988) used a combination of chemotherapy, snail control, 
provision of clean water and sanitation and infrastructural development [4, 5].  Such multi-
approach control programs are now the exception rather than the rule [6].  Due to the low 
cost, safety and high efficacy of praziquantel, mass drug administration (MDA) has become 
the mainstay of national control programs.  
 
Mass Drug Administration began in Uganda in 2003 and 400,000 treatments of 
praziquantel were distributed that year, with the support of the Schistosomiasis Control 
Initiative [7-9]. This has since expanded to the treatment of approximately 1.5 million 
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children annually [10], resulting in significant reductions in S. mansoni prevalence, 
intensity and associated morbidity [11, 12]. Similar successes have been reported in other 
countries implementing MDA [13]. Spurred by these results, the World Health Organization 
(WHO) revised their strategic plan from disease control to the interruption of transmission 
in certain African countries, including Uganda, by 2025 [14]. With the exception of certain 
islands implementing snail control [15], this ambitious plan remains solely reliant on MDA 
with praziquantel. Monitoring the continued efficacy of praziquantel is therefore 
paramount.  
 
In the field, S. mansoni is commonly detected by the presence of eggs in stool, typically 
using the Kato-Katz thick smear method which is inexpensive and practical in low-resource 
settings [16]. As the test suffers from poor sensitivity, though close to 100% specificity 
[16], multiple readings improves the chances of detecting eggs in the stools of infected 
patients [17]. Egg counts measured before and after treatment are used to quantify drug 
efficacy as the egg reduction rate (ERR). The WHO has set a tentative ERR threshold of 90% 
as an indicator of optimal efficacy [18]. 
 
The sample ERR is typically calculated directly from egg count data by applying a simple 
formula (see Equation 1 in Methods). This is a population-level approach that is not readily 
compatible with individual patient data [19]. Such data are better analysed using statistical 
techniques specifically designed for longitudinally repeated measures and that permit 
estimation of ERRs (and their associated uncertainties) for individual patients [20]. These 
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methods can also be used to estimate distributions of ERRs from individual patients, which 
are useful for identifying poor responses and gradual shifts in anthelmintic efficacy [19,20].  
 
Here we assess the effect of previous rounds of MDA on the efficacy of praziquantel against 
S. mansoni infections in primary schoolchildren in eastern Uganda. We explore whether the 
number of previous rounds of MDA is associated with efficacy of praziquantel, estimated as 
an ERR. We analyse data from a repeated cross-sectional study of six schools that have 
received varying numbers of MDA rounds over a period of eleven years. We fit a statistical 
model to data on schistosome egg counts before and 25-27 days after treatment, estimating 
praziquantel efficacy using Bayesian techniques at the levels of individual patients and 
schools. 
 
Methods  
Study Site  
 
Fieldwork was conducted in Mayuge and Tororo districts, Uganda from May – July 2014 
(Figure 1). Six government-run primary schools were included into the study, five from 
Mayuge district and one from Tororo (Table 1; see Supplementary Material for GPS 
coordinates). None of the schools had piped running water or a pump and all sanitation 
facilities were drop pits. Approximately 6 months had elapsed between the previous round 
of MDA and the present study taking place. The MDA in Tororo in 2013 was the first MDA 
in this district and achieved only 21% coverage. MDA in Mayuge has been ongoing since 
2003, although MDA did not take place in any schools during 2008-9. 
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Enrolment 
 
At baseline 769 children were recruited from six primary schools. Children were randomly 
sampled within the age group 6-12 years and by sex. Children enrolled in the study were 
examined from 1-3 days before and 1-3 days after treatment with duplicate Kato-Katz 
slides per stool per day (i.e. a maximum of 12 counts per child, up to 6 pre and 6 post 
treatment). Treatment with praziquantel and albendazole, for soil-transmitted helminths 
(STH), was overseen by a nurse and children were observed for one hour following 
treatment to check for side effects and to exclude from the efficacy analysis any children 
who vomited within an hour (Figure 2). Children were followed up 25-27 days after 
treatment.  
 
Our inclusion criteria for the baseline analysis was that the children were present for at 
least one day before treatment and so provided a minimum of 2 Kato-Katz thick smears for 
diagnosis. This gave a sample size of n = 749 patients. Our inclusion criteria for the efficacy 
analysis were that the child was i) present for at least 1 day before and 1 day after 
treatment; ii) positive for S. mansoni at baseline and, iii) successfully treated with 
praziquantel and albendazole without vomiting. This gave a sample size of n = 414 patients 
(Figure 2).  
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Sample Egg Reduction Rate (ERR) 
 
We calculated the sample ERR using  
 
      (1) 
 
where the mean is calculated at the level of the school using all egg counts, rather than 
individual level averages. We used a non-parametric percentile block bootstrap method to 
calculate confidence intervals (CIs) associated with the sample ERR. Block bootstrap 
methods [20] account for correlation among observations (egg counts) from the same 
individual by randomly sampling (with replacement) blocks of data; here, all of an 
individual’s egg counts before and after treatment. We also applied this method to calculate 
CIs associated with mean egg counts before and after treatment. Details are given in 
Supplementary Methods. 
 
Covariates 
 
The schools were selected to give a variety of different MDA histories: one round for 
Kocoge; an estimated five rounds for Bukoba and Bukogabo; eight rounds for Musubi and 
nine rounds for Bugoto and Bwondha, which we classify as low, medium and high previous 
exposure to MDA respectively (Table 1). While school level MDA records were not available 
for Bukoba and Bukagabo, the number of MDA rounds were estimated based on 
information from Mayuge district officials and district-level MDA coverage from the 
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Ugandan Ministry of Health. The sex and weight of each child were recorded at enrollment. 
Egg counts for STHs (Ascaris lumbricoides, Trichuris trichiura and hookworm species) were 
also collected.  Weight was categorized as: low, <22kg; medium, 22-26kg and high, >26kg. 
Age and height were recorded, but dropped as covariates due to their correlation with 
weight. Co-infection with STH was defined as a binary variable. 
 
Statistical Analysis 
 
We developed and fitted a statistical model to the S. mansoni egg count data in a Bayesian 
framework using an approach outlined elsewhere [19, 21] and implemented in R [22] with 
the package MCMCglmm [23]. Full mathematical details are given in Supplementary 
Methods. Here we give a brief description of the features relevant to the estimation of 
patient ERRs. The key distributional assumption of the model is that egg counts measured 
from a patient at a specific time (before or after treatment) are Poisson distributed, with an 
observation level random effect permitting extra-Poisson variation or overdispersion [19, 
22, 23]. 
 
The key systematic component of the model is a log-linear regression structure that 
describes the change in egg counts after treatment, x = 1, compared to before treatment, x = 
0, in a multiplicative fashion such that the accompanying treatment effect coefficient β 
quantifies the relative change and the ERR is given by 1 – exp(βx). Covariates enter the 
model as fixed effects interacting with x, allowing ERRs to vary among patients of different 
sex, weight category and MDA exposure. Random effects coefficients, specific to each 
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patient, school and also interacting with x, permit ERRs to vary among patients and among 
schools sharing the same (fixed effect) covariate values. The correlation (ρ) between 
random effects (at individual patient or school levels) quantifies the association between 
egg counts before treatment and the treatment effect. A positive correlation at the 
individual level corresponds to individuals with higher than average egg counts at baseline 
tending to have lower ERRs and vice versa for a negative correlation. 
 
Results 
Summary epidemiological statistics 
 
Baseline epidemiological data for each of the six schools are shown in Table 1. The analysis 
was performed on 749 children who were present for at least one day of sampling before 
treatment. The prevalence of S. mansoni at baseline in the schools surveyed ranged from 
44.92% in Bukoba to 94.49% in Musubi. The arithmetic mean eggs per gram (EPG) was 
calculated by averaging over egg counts from schools and multiplying by a factor of 24, 
rather than from the fitted model, to be comparable with previous studies in Uganda [24]. 
The intensity of infection varied seven-fold among schools, from 92 EPG (95% confidence 
interval, CI:  67-128 EPG) in Bukoba to 742 EPG (95% CI: 518-973 EPG) in Bwondha.  
 
Of the 414 children included in the praziquantel efficacy analysis (Figure 2), 209 (50.48%) 
were female and the age range was 6-12 years with a median of 8.5 years. There were no 
significant differences in the fixed effect characteristics of included and excluded children 
(see Supplementary Material). A total of 4102 egg counts (approximately 10 per child) 
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were collected from Kato-Katz smears: 2090 before treatment and 2012 after treatment. 
Co-infections of S. mansoni and STH were present in 141 patients (34.06%) of which the 
majority were hookworm (139, 33.57%).  
 
Variation in praziquantel efficacy among children 
 
The estimated posterior distributions of the model coefficients associated with 
praziquantel efficacy are summarized in Table 2 as means and 95% Bayesian credible 
intervals (BCIs). We also present the (Bayesian) p values [25] associated with each 
posterior distribution. Negative coefficients (or their exponent < 1) associated with 
covariate-treatment interactions indicate a lower egg count after treatment and a higher 
ERR and vice versa for positive coefficients (or their exponent >1). Because the model is 
specified at the level of the individual patient, coefficients are interpreted as reflecting the 
fixed covariate effect on a typical child (i.e. when the random effects adjustments are equal 
to 0) [21]. 
 
The negative coefficients associated with egg counts measured after treatment from 
different low (β = -1.32, p = 0.10) and medium (β = -1.42, p = 0.060) MDA exposure 
categories indicates that a typical child within a school that has received fewer previous 
MDA rounds has a higher ERR than a typical child in a school that has received more 
previous rounds of MDA, though these effects are not statistically significant. The positive 
coefficients associated with medium (β = 0.83, p = 0.0024) and low (β = 1.21, p = 0.048) 
weight categories indicate that a typical child in these weight categories has a lower ERR 
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than a typical child in the high weight category. The coefficients of other covariates fitted as 
interaction terms in the model (sex and co-infection with STH) are not statistically 
significantly different from zero. The estimated negative correlation between children’s egg 
counts before treatment and the treatment effect (ρ = -0.17, see Supplementary Methods) 
indicates that children with higher egg counts tend to have higher ERRs, albeit the effect is 
of only marginal statistical significance (95% BCI: -0.32, -0.019).  
 
Individual children’s ERRs are variable within each school and MDA exposure category, 
however in the high MDA exposure category 16.42% (95% BCI: 13.42%, 19.78%) of the 
posterior mean individual ERRs are below the 90% reference efficacy [18] compared with 
4.55% (95% BCI: 1.22%, 9.76%) and 5.11% (95% BCI: 0.00%, 10.94%) in the medium and 
low categories respectively (Figure 3). The BCIs quantify the considerable uncertainty in 
the individual mean ERR estimates and reflects both the variation among egg counts 
measured from the same child and the number of counts measured per child, which ranged 
from 4 to 12. The estimated ERRs and associated 95% BCIs for each child, stratified by 
school and MDA exposure category are shown in Figure 3.  
 
Variation in the efficacy of praziquantel among schools 
 
We marginalized (averaged) over the posterior distributions of the fixed and random 
effects coefficients to yield average ERRs by schools and MDA exposure categories. Average 
ERRs are generally high and 90%, however we find that schools within the high MDA 
exposure category show a significantly lower ERR (91.49%; 95% BCI 88.23%, 93.64%) 
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compared with both the medium (98.04%; 95% BCI 96.13%, 99.08%) and low (97.81%; 
95% BCI 95.5%, 98.96%) categories, having adjusted for other covariate fixed effects 
(Table 3). For comparison with the model-derived estimates and for comparability with 
previous studies we also calculated sample estimated ERRs. The sample estimated ERRs 
follow the same pattern as the model-derived ERR estimates, with more intensively treated 
schools showing lower ERRs, and fall within the corresponding 95% BCI (Table 3). 
Resampling from the dataset using fewer egg count readings suggests that 3 days of 
duplicate Kato-Katz readings before and after treatment were necessary to detect the 
differences in anthelmintic efficacy we observe between MDA exposure categories (see 
Supplementary Material). 
 
The posterior distributions of average ERRs by school and MDA exposure category are 
shown in Figure 4. The distribution associated with the high MDA exposure category is 
separated from the distribution of the medium and low categories, in accordance with a 
lower average efficacy of praziquantel for children in schools with a higher past exposure 
to MDA. 
  
Discussion 
 
We have tested the impact of a school’s past exposure to MDA with praziquantel on present 
treatment outcomes for S. mansoni. We have demonstrated through the use of an 
appropriate statistical modeling technique that treatment efficacy, as quantified by the 
ERR, is lower in schools that have been treated in eight or nine previous MDA rounds 
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compared with other schools from the same or nearby districts that have undergone five or 
fewer rounds of MDA with praziquantel.  
 
From the baseline data we collected from the schools (Table 1), we found a high prevalence 
(>84%) and infection intensity (>400 EPG) in Bugoto, Bwondha and Musubi, the schools 
that have undergone the highest number of previous MDA rounds. It is surprising that S. 
mansoni infection remains entrenched within these foci despite up to nine rounds of MDA. 
We concur that persistence of the parasite population is driven by continued re-infection 
from transmission hotspots in Lake Victoria [26]. It is concerning for efforts to halt 
transmission of S. mansoni through MDA alone that areas with high infection intensity are 
so resilient to repeated treatments.  
 
We found that the weight of children was associated with estimated ERRs. The dose of 
praziquantel is weight-standardized at 40mg/kg and hence one would not expect 
differences in drug efficacy among children of different weight. The lower ERR in lighter 
children suggests that they are not receiving a sufficient dose, perhaps indicating that there 
is a minimum therapeutic dose that lighter children are failing to receive. There could also 
be an age-dependent effect (as weight and age are closely correlated) reflecting synergism 
between the development of protective immune responses and the antischistosomal 
activity of praziquantel [27]. 
 
A recent meta-analysis of praziquantel efficacy reported an average ERR of 89.1% (95% CI 
83.3%, 94.2 %) among treated S. mansoni infections in schoolchildren with a median follow 
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up time of 5 weeks [28]. The comparable estimates of the ERR in this study are the average 
school-level estimates, including those for different MDA exposure categories. None of our 
estimates extend below the lower CI of the meta-review estimates, suggesting that 
praziquantel remains broadly efficacious in all our study sites (although heterogeneity in 
study design will naturally widen CIs estimates from a meta-analysis compared to 
estimates obtained from a single study). However, of concern is the significant difference in 
estimated ERRs we observe between schools that have received more previous rounds of 
MDA compared to those that have received fewer rounds (Table 3, Figure 4).  
 
Variation in anthelmintic efficacy is driven by parasite and host-specific factors. Without 
long-term longitudinal data (i.e. on the scale of years, over multiple rounds of MDA), or 
baseline data from before MDA commenced, we cannot determine whether heterogeneities 
among ERRs, at either the individual or school levels, are static or changing temporally. A 
systematic decline in ERRs could be indicative of increasing parasite tolerance or emerging 
resistance to praziquantel [29, 30]. Intervention programmes using MDA should 
incorporate regular assessment of drug efficacy into their monitoring and evaluation 
protocols. 
 
A recent analysis of praziquantel efficacy against S. mansoni found variation among ERRs 
from individual patients to be greater in Uganda than in other countries [21]. Schistosoma 
mansoni parasites in Uganda have been observed to be more genetically diverse than 
elsewhere [31], which could be driving more variable treatment outcomes. Host factors 
such as genetic variation or differences in nutritional status are unlikely to be sufficient to 
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explain the variation in ERRs because of the spatial proximity and similar patterns of 
subsistence in the schools surveyed (Figure 1). It is also unlikely that different rates of 
reinfection are driving substantive differences among patient ERRs.  This is because the 
time to follow up (25-27 days) is short and the statistical model is designed to control for 
different rates of reinfection by modeling the intensity of infection after treatment relative 
to the intensity before treatment such that each individual acts as its own control.  
 
We are left with the possible explanation that reduced praziquantel efficacy is caused by 
drug-tolerant genetic variants within the S. mansoni population in highly treated areas. 
Genetic changes associated with drug resistance have been associated with drug-induced 
selection pressures in human and veterinary helminthiases [32-35]. Ultimately, drug-
induced resistance can only be confirmed by linking changes in resistance allele 
frequencies to phenotypic indicators of drug tolerance or reduced susceptibility. As neither 
the precise mode of action of praziquantel nor the genetic basis of resistance in 
schistosomes are completely understood [36], the powerful approaches offered by next-
generation sequencing will be essential to scan for selection across whole-genomes [37, 
38]. Such approaches would help to establish if parasite genetic variation could be driving 
the degree of variation in praziquantel efficacy that we have observed in this study. 
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Figure Legends 
 
Table 1. Sample estimates of the prevalence and intensity of Schistosoma mansoni 
infection in children from six primary schools in eastern Uganda before treatment 
with praziquantel. The number of previous rounds of Mass Drug Administration (MDA) 
the school has been exposed and corresponding MDA Exposure Categories are shown. 
Infection intensity is quantified as the arithmetic mean number of egg per gram of faeces 
(EPG). Confidence intervals (CIs) are calculated using a block bootstrap approach to 
account for correlation among egg counts repeatedly measured from the same child. 
 
Table 2. Estimated coefficient posterior distributions of the generalized linear mixed 
model fitted to Schistosoma mansoni egg counts collected from 414 children from six 
primary schools in eastern Uganda before and after treatment with praziquantel. The 
posteriors are summarised by their mean and 95% Bayesian credible interval (BCI). The 
coefficients estimates all interact with treatment and thus correspond to the effect of the 
covariate on the egg reduction rate (ERR). Negative coefficients (or their exponent < 1) 
associated with covariate-treatment interactions indicate a lower egg count after treatment 
and a higher ERR and vice versa for positive coefficients (or their exponent >1) (see 
Methods). 
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Table 3. Estimated average egg reduction rates (ERRs) of Schistosoma mansoni in 
414 children from six primary schools in eastern Uganda following treatment with 
praziquantel. Sample estimates are calculated using Equation 1 in Methods, Sample Egg 
Reduction Rates with 95% confidence intervals (CIs) calculated using a block bootstrap 
approach to account for correlation among egg counts repeatedly measured from the same 
child. Model estimates and 95% Bayesian credible intervals (BCIs) correspond to the 
posterior distribution of the average ERR by mass drug administration (MDA) exposure 
category and by school calculated by marginalizing (averaging) over the appropriate fixed 
and random effects coefficients of the fitted generalized linear mixed model.  
 
Figure 1. Maps of study sites. Panel A is a map of Uganda in an East African context with 
Mayuge and Tororo districts highlighted. Panel B shows the location of the schools 
surveyed in Mayuge district. Panel C shows the location of the schools surveyed in Tororo 
district. 
 
Figure 2. Flow diagram of patient recruitment and exclusion criteria for egg 
reduction rate analysis after treatment with praziquantel (PZQ) and albendazole 
(ALB). 
 
Figure 3. Estimated egg reduction rates (ERRs) of Schistosoma mansoni from 414 
children in eastern Uganda treated with praziquantel. Individual estimates are 
stratified by school in panel A and by mass drug administration (MDA) exposure category 
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in panel B. Black points indicate the mean of the posterior distribution and the grey bars 
indicate 95% Bayesian credible intervals (BCIs). The hashed lines correspond to the 
nominal reference threshold of 90% suggested by the World Health Organization. Note that 
the BCIs have been truncated at 1 and 99%. Category of MDA reflects the previous number 
of rounds of treatment with praziquantel the schools have received (high is 8 or 9; medium 
is 5; low is 1). 
 
Figure 4. Posterior distribution of average egg reduction rates (ERRs) of 
Schistosoma mansoni in 414 children from 6 primary schools in eastern Uganda 
treated with praziquantel. The average ERRs are stratified by school in panel A and by 
mass drug administration (MDA) exposure category in panel B. The posteriors were 
constructed by marginalizing over the fixed and random effects coefficients estimated from 
the generalized linear mixed model. The coloured hashed lines indicate the mean of the 
posterior. Category of MDA reflects the previous number of rounds with praziquantel the 
schools have received (high is 8 or 9; medium is 5; low is 1).  
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Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
School  
 
District  MDAa 
Exposure 
Category 
Recruited  Tested at 
Baseline  
Positive for 
S. mansoni 
(%) 
Mean EPGb  
(95 % CIc) 
Bwondha  Mayuge  High  
(9 rounds) 
98  96 87 
(90.63) 
742 
(518-973) 
Bugoto  Mayuge  High  
(9 rounds) 
183  170 144 
(84.71) 
436 
(339-534) 
Musubi  Mayuge  High  
(8 rounds) 
128  127 120 
(94.49) 
465 
(362-600) 
Bukoba  Mayuge  Medium 
(5 rounds)d 
120  118 53 
(44.92) 
92 
(67-128) 
Bukagabo  Mayuge  Medium  
(5 rounds)d 
120  118 57 
(48.31) 
306 
(197-442) 
Kocoge  Tororo  Low  
(1 round) 
120  120  81 
(67.50) 
347 
(245-456) 
Total   769 749 542 
(72.36) 
382 
(338-446) 
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a Mass Drug Administration b Eggs Per Gram c Confidence Interval  
d Estimated from district-level MDA coverage from Ministry of Health
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Table 2.  
a Bayesian Credible Interval b not applicable; c mass drug administration; d soil-transmitted helminth 
 
Covariate Category Coefficient 
posterior mean 
(95% BCIa) 
Exponent coefficient 
posterior mean (95% 
BCI) 
Bayesian 
p value  
Intercept NAb 2.32 (1.36, 3.25) 10.79 (2.17, 21.19) 0.01 
Treatment NA -5.65 (-6.81, -4.55) 3.91x10-3 (5.82x10-4, 
8.86x10-3) 
<0.01 
MDAc exposure  Low (1 round) -1.33 (-3.20, 0.48) 0.328 (3.36x10-9, 1.03) 0.10 
 Medium (5 rounds) -1.42 (-2.94, 0.25) 0.293 (9.34x10-13, 0.793) 0.06 
Weight Low (<22kg) 1.21 (0.40, 2.03) 3.57 (1.12, 6.72) <0.01 
 Medium (22-26kg) 0.83 (0.01, 1.65) 2.45 (0.845, 4.74) 0.05 
Sex  Male 0.13 (-0.48, 0.78) 1.19 (5.32, 1.98) 0.67 
Co-infection with STHd Positive 0.27 (-0.40, 0.99) 1.37 (0.569, 2.43) 0.44 
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Table 3. 
 
 
   ERRa (%) 
 
   ERR (%) 
 
MDA 
exposure 
category 
n Cleared 
(%) 
Sample 
(95% CI) 
Model 
(95% BCI) 
School n Cleared 
(%) 
Sample 
(95% CI) 
Model 
(95% BCI) 
High 
(8 or 9 
rounds) 
268 151 
(56.34) 
92.10 
(87.42, 95.71) 
91.49 
(88.23, 93.64) 
Bwondha  68 40 
(58.82) 
94.27 
(88.13, 98.26) 
94.19 
(90.65, 96.34) 
Bugoto  103 62 
(60.19) 
89.63 
(77.65, 96.65) 
91.20 
(85.40, 94.50) 
Musubi  97 49 
(50.51) 
91.98 
(82.35, 97.69) 
89.90 
(83.53-93.49) 
Medium 
(5 rounds)b 
82 68 
(82.93) 
98.71 
(97.50, 99.53) 
98.04 
(96.13, 99.08) 
Bukoba  42 37 
(88.10) 
98.98 
(97.55,99.85) 
98.50 
(96.26-99.52) 
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Bukagabo 40 31 
(77.50) 
98.58 
(96.50, 99.64) 
97.56 
(94.59-99.01) 
Low 
(1 round) 
64 45 
(70.31) 
98.87 
(98.07, 99.60) 
97.81 
(95.51, 98.96) 
Kocoge  64 45 
(70.31) 
98.87 
(98.07, 99.60) 
97.81 
(95.51-98.96) 
 
 
a Egg Reduction Rate b Estimated from district-level MDA coverage from Ministry of Health
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Figure 2.  
 
 at R
oyal V
eterinary College on A
ugust 1, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
33 
  
 at R
oyal V
eterinary College on A
ugust 1, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
34 
Figure 4. 
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